Brand Name
Recorlev
Generic Name
Levoketoconazole
View Brand Information FDA approval date: December 30, 2021
Classification: Cortisol Synthesis Inhibitor
Form: Tablet
What is Recorlev (Levoketoconazole)?
RECORLEV is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of Use RECORLEV is not approved for the treatment of fungal infections. The safety and effectiveness of RECORLEV for the treatment of fungal infections have not been established. RECORLEV is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative Limitations of Use RECORLEV is not approved for the treatment of fungal infections
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment